Covid-19 roundup: Inovio enlists plasmid manufacturer to replace the one it’s in legal feud with; Cyberattacks spotted targeting vaccine distribution 

Share:

Share:With its Phase II trial finally underway, Inovio has enlisted another key manufacturing partner to hit its goal of hundreds of millions of doses of its DNA vaccine — filling the role of a contract manufacturer it’s still in a legal standoff with. Japan’s Kaneka Eurogentec is tasked with plasmid production, for which Inovio has […]

DECENTRALIZED TRIALS & RESEARCH ALLIANCE (DTRA) LAUNCHES TO DEMOCRATIZE AND ACCELERATE CLINICAL TRIALS

Share:

Share:December 10, 2020 – An historic alliance of life sciences and healthcare organizations seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The Decentralized Trials & Research Alliance (DTRA) plans to unite stakeholders, including healthcare companies, regulators, patient groups and research organizations, with a mission to make clinical trial participation widely accessible […]

Report Study | Impact of COVID-19 on the Global Rare Neurodegenerative Disease Treatment Market

Share:

Share:A new study on the Rare Neurodegenerative Disease Treatment market provides a detailed overview of the demands and consumptions of various products/services associated with the growth dynamics of the market. The in-depth market estimation of various opportunities in the segments is expressed in volumes and revenues during the forecast period 2020 to 2030. The insights and […]

REGENERON’S ANTIBODY COCKTAIL REGN-EB3 (INMAZEB®) IS FIRST FDA-APPROVED TREATMENT FOR EBOLA (ZAIRE EBOLAVIRUS)

Share:

Share:In a large clinical trial, Inmazeb showed superiority compared to other investigational agents (ZMapp and remdesivir) with respect to mortality; treatment was most effective when given early in the course of disease1 Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) is a novel anti-viral antibody medicine developed using the same ‘rapid response’ technologies as Regeneron’s investigational COVID-19 antibody […]

Bausch Health And BHVI Announce Exclusive Global Licensing Agreement For Myopia Control Contact Lens

Share:

Share:Second Exclusive License Strengthens Bausch + Lomb’s Global Research Focus on Myopia SYDNEY and LAVAL, QC, Oct. 15, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, its leading global eye health business, along with BHVI, an Australian not-for-profit organization with an international focus on vision research, announced today that an […]

Japan Grants Patent to Brainstorm Covering Technique for NurOwn

Share:

Share:The Japan Patent Office has granted a patent to Brainstorm Cell Therapeutics covering the proprietary technique that generates the company’s cell-based therapy NurOwn from mesenchymal stem cells (MSCs). Through this technique, researchers can harness MSCs directly from a patient and mature them into cells that produce high levels of neurotrophic factors, which are compounds that […]